All nucleated cells of jawed vertebrates present antigenic peptides (APs) at their surface through the major histocompatibility complex class I (MHC-I) presentation pathway (1) . APs are 8-to 12-amino acid long and reflect the inherent metabolic cellular activity. Initial clinical trials using vaccines targeting tumor antigens (TA) have not met their expectations. The main failures have been associated with immunosuppressive mechanisms and with a suboptimal choice of antigens (2, 3) . One of the important events that drives tumor immunoselection and that is correlated with a poor prognosis is the loss or the downregulation of MHC-I antigen presentation by tumor cells (4, 5) . The latter can escape cytotoxic T lymphocyte (CTL) and natural killer cell recognition thanks to defects in components of the MHC-I pathway (6) . Moreover, along with the overall decrease in MHC-I antigen presentation, the very nature and the amount of antigens presented at the cell surface, namely the MHC-I immunopeptidome, is of critical importance for immune recognition. For example, the loss of expression at the tumor cell surface of a specific TA identified and targeted with immunotherapy, such as Her/neu in breast cancer or CEA in colon cancer, leads to immune evasion (7, 8) . To counteract this phenomenon, current strategies aim at enlarging the range of targeted cancer peptides and restoring MHC-I antigen presentation (9) (10) (11) (12) .
In order to understand the dynamic of the MHC-I immunopeptidome, we focused on the source of APs for the MHC-I presentation pathway. Exploring the concept of Defective Ribosomal Products (DRIPs) (13) (14) (15) (16) , we showed that one of the most important source of APs is a pioneer translation event that occurs on pre-mRNAs, before introns are spliced out, and independently of the translation of the corresponding full length proteins. Produced non-canonical peptides can therefore be derived from intronic sequences, 3' or 5' UTR regions as well as alternative reading frames. These polypeptides are described as Pioneer Translation Products (PTPs) (17, 18) . The discovery of PTPs emphasizes the existence of a nuclear translational mechanism of precursors-mRNAs that participates to the production of MHC-I peptides (MIPs) by generating suitable polypeptides for the MHC-I pathway. Moreover, PTPs play a role in the dynamic of cancer development. When inoculated into mice, it has been shown that cancer cells presenting PTP-derived antigens at their surface can be recognized by specific T-cells leading to tumor growth reduction. Besides, purified PTPs containing a model epitope efficiently promote anti-cancer immune response when injected as a peptide vaccine into mice (19) .
Precursor-mRNA (pre-mRNA) splicing is catalyzed in the nucleus by the spliceosome, a conserved and dynamic multi-RNA/protein complex composed of five small nuclear RNAs (snRNAs) in interaction with over 180 proteins (20) . A growing number of studies report that the deregulation of the spliceosome complex entails aberrant splicing patterns in many cancers contributing to abnormal tumor cell proliferation and progression (21) (22) (23) (24) . Furthermore, cancer cells have different intracellular mechanisms to shape the pool of peptides presented on MHC-I molecules at their surface, leading to the reduction of their immunogenicity and allowing them to escape from T-cell recognition (6, 25) . In a recent study, we observed that splicing inhibition positively modulate the surface presentation of a PTP-derived model antigen in healthy cells treating with isoginkgetin (18) . The latter molecule has been reported to inhibit the spliceosome during the early stages of its assembly (26). From these observations, the link between splicing inhibition and antigen presentation in cancer cells became of particular interest for us and splicing inhibitors appeared as one potential strategy to render tumor cells more visible to CTL. Since 2011, recurrent spliceosome mutations have been reported in several cancers. Among strategies developed to render tumor cells more visible to CTL, a novel class of anticancer molecules has been of particular interest for us: the splicing inhibitors (21) . Several natural products and their synthetic analogues have been reported to inhibit the spliceosome, including pladienolides B and D, spliceostatin A, FR901464, E7107, isoginkgetin and madrasin. Beyond their previously reported cytotoxic activities (27,28), we aimed at testing their effect on PTP production and antigen presentation.
Here we show that the biflavonoid isoginkgetin and its water-soluble derivative IP2 we generated enhance the presentation of PTP-derived antigens in human and mouse cancer cells in-vitro.
In addition, IP2 induces a long-lasting anti-cancer immune response in vivo. Finally, IP2 was shown to re shape the MHC-I immunopeptidome, leading to a new peptide representation at the cell surface.
Our findings suggest a new mechanism of action of those splicing inhibitors that modulate the presentation of MIPs at the cancer cell surface by enhancing the presentation of PTP-derived antigens and potentiate the antitumor immune response.
Results

Splicing inhibition increases the presentation of conventional and non-conventional antigens in cancer cells
To improve antigenicity and immune recognition of cancer cells, we determined whether isoginkgetin was able to modulate positively the expression and the presentation of tumor associated PTP-derived antigens at the surface of cancer cells. For that purpose, the human melanoma cell line A375, the human lung cancer cell line A549 and the normal human fibroblast lung cell line MRC5 transiently expressing the mouse MHC-I H-2K b molecule and the intron-derived SL8 epitope within the β -Globin gene construct (Globin-SL8-intron) were treated at different doses of isoginkgetin for 18h. The overall expression of the MHC-I H-2K b molecules at the cell surface upon treatment was assessed by B3Z activation. Treatment with isoginkgetin increases intron-derived SL8-antigen presentation in the three cell types, in a dose dependent manner (Fig. 1A) . In parallel, the same experiment was performed on the mouse sarcoma MCA205 and mouse melanoma B16F10 cell lines that were transiently expressing the Globin-SL8-intron construct. In accordance with the previous results, isoginkgetin elicited an increase in the intron-derived SL8 antigen presentation, in a dose dependent manner (Fig. 1B) . To investigate further the impact of isoginkgetin on PTP presentation, MCA205 and B16F10 cell lines transiently expressing the exon-derived SL8 epitope within the β -Globin gene construct (Globin-SL8-exon) or the splicing independent Ova-derived SL8 were treated with increasing doses of the compound. We observed that isoginkgetin increases splicing dependent but not splicing independent SL8 presentation in a dose dependent manner (Figs. 1C and 1D ). Those results show that isoginkgetin-induced PTP-presentation is mediated through altered splicing events.
This suggests an action of isoginkgetin during the production stage of PTPs and not downstream in the MHC-I antigen presentation pathway.
Moreover, we assessed the ability of a second splicing inhibitor, the madrasin, to increase PTP-derived antigen presentation in cancer cells. Interestingly, as isoginkgetin did, madrasin increased intron-derived SL8 presentation in the MCA205 and B16F10 mouse cell lines and in the A375 human melanoma cell line (Figs. 1E and 1F). However madrasin was shown to be more toxic than isoginkgetin at the effective doses ( Supplementary Fig. S1 ). In contrast, when treated with the chemotherapeutics gemcitabine or cyclophosphamide, the same cell lines that express the SL8 epitope from an intron did not show any significant modulation of the antigen expression ( Supplementary Fig.   S2 ), apart from MCA205 and A549 cells treated with gemcitabine. Taken together, those results suggest a specificity of action of the splicing inhibitor family on antigen presentation which is not shared with molecules with other activities.
Finally, we observed that the expression of the MHC-I H-2K b molecules at the cell surface varies upon treatment depending on the cell type ( Supplementary Fig. S3 ) but is not correlated to the effect of the drugs on SL8 antigen presentation.
Overall, these results show that the natural product isoginkgetin acts as a enhancer of the PTPderived antigen presentation in cancer cells independently of the epitope setting, i.e. in exonic or in intronic sequences, and independently of the cell type. Moreover, the effects of both isoginkgetin and madrasin treatments shed further light on the importance of the splicing event for the production and the presentation of MHC-I antigens in cancer cells. Finally, they support the idea that pre-mRNAs are a source for antigen presentation when the spliced machinery is impaired.
Isoginkgetin treatment slows down in vivo the growth of intron-derived SL8-expressing tumors.
Antigen abundance at the cell surface has been demonstrated to be a key parameter in determining the magnitude of the CD8+ T cell response and hence in defining immunodominance (29). The SL8 peptide is highly immunogenic in vivo. Looking at SL8-specific T-cell activation in vitro, we observed an increase in the abundance of the SL8 expression at the cancer cell surface after splicing inhibition. In order to test this hypothesis in vivo, we first looked at the impact of isoginkgetin treatment on the growth of tumors expressing the intron-derived SL8 peptide. For that purpose, MCA205 sarcoma cells and B16F10 melanoma cells stably expressing the Globin-SL8-intron construct were inoculated subcutaneously into mice. At days 5, 10 and 15 post tumor inoculation, the mice were injected intraperitoneally with isoginkgetin and the tumor growth was monitored ( Fig. 2A) .
In mice bearing MCA205 globin-SL8-intron tumors, we observed a significant reduction of tumor size, over 60% at day 27 after challenge with 12 and 18mg/kg of isoginkgetin ( Fig. 2B and Supplementary Fig. S4A , left panels). The impact of isoginkgetin treatment on B16F10 globin-SL8-intron tumor growth is lower with over 30% of tumor reduction at day 18 after challenge with 12 and 18mg/kg of isoginkgetin ( Fig. 2B and Supplementary Fig. S4A , right panels). To assess the link between SL8 overexpression and tumor growth reduction in vivo after isoginkgetin treatment, we performed the same experiment in mice inoculated with either MCA205 or B16F10 wild type (WT) cells. No significant reduction of the growth of MCA205 WT ( Fig. 2C and Supplementary Fig. S4B , left panels) and B16F10 WT ( Fig. 2C and Supplementary Fig. S4B , right panels) was observed after treatment with 12 and 18mg/kg of isoginkgetin. Taken together these results show that isoginkgetin induced PTP presentation and tumor growth reduction is mediated through altered splicing events.
We then assessed the requirement of the immune system for isoginkgetin to reduce tumor growth. Immunodeficient Nu/Nu nude mice were inoculated subcutaneously with either MCA205 or B16F10 cells stably expressing the Globin-SL8-intron construct or WT cells, and thereafter treated under the same conditions as previously described ( Overall, these results show that tumor growth slow down upon isoginkgetin treatment requires the presence of an active immune response in vivo, and suggest that the increase in the expression of an immunodominant epitope drives the antitumor immune response.
The water-soluble IP2 and M2P2 compounds derived from the natural isoginkgetin product inhibit the splicing with reduced cytotoxicity.
With the aim of transferring the isoginkgetin compound to the clinic, two of its intrinsic properties were limiting: its hydrophobicity which reduces its bioavailability and its cytotoxicity on both normal and tumor cells. Therefore, derivatives of the natural isoginkgetin product were synthesized and tested for their ability to inhibit the splicing machinery, to increase PTP-derived antigens in vitro as well as to reduce tumor growth in vivo.
From the commercial isoginkgetin (Fig. 3A) , extracted from leaves of the maidenhair tree, Ginko biloba, the derivatives IP2 (Fig. 3B ) and M2P2 ( Fig. 3C) were synthesized. The synthesis route of each compound is provided in Figure S5 . Briefly, the synthesis of IP2 (referred as compound 2 in the schematic) was accomplished by the phosphorylation of isoginkgetin employing in situ formation of diethylchlorophosphite to provide compound 1. Further cleavage of the ethyl ester protective groups with iodotrimethylsilane afforded the phosphoric acid intermediate, which was immediately treated with sodium hydroxide to complete a practical route to the disodium phosphate prodrug. For the synthesis of the M2P2 molecule, the remaining two phenol groups of compound 1 were alkylated using methyl iodide to furnish compound 3. Treatment of the latter under similar conditions to prepare compound 2 from compound 1 gave the disodium phosphate prodrug 4 or M2P2, whereas its reaction under basic conditions provided compound 5.
The water solubility of IP2 and M2P2 was found to be considerably higher than that of the parent compound isoginkgetin (data not shown). In addition, we tested the ability of IP2 and M2P2 to inhibit the splicing of the Globin-SL8-intron gene product in MCA205 and B16F10 cells.
Interestingly, IP2 and M2P2 provide two distinct patterns of splicing inhibition in each cell line. IP2 treatment increases the presence of non-spliced RNA products in both cell lines, just as isoginkgetin or madrasin do. In contrast, M2P2 treatment does not impact splicing in B16F10 cells while it has a strong impact on splicing in MCA205 compared to IP2, isoginkgetin and madrasin treatment (Fig.   3D ). Hence, IP2 and M2P2 seem to inhibit the splicing machinery in different ways. Importantly, we observed that the splicing pattern of IP2 is comparable to that of isoginkgetin and madrasin for the studied gene product. Finally, both IP2 and M2P2 compounds display no toxicity toward MCA205
and B16F10 WT cells at the doses tested as assessed by MTT assay (Fig. 3E) (Fig. 4C , left panel and Supplementary Fig. S7A , left panel). In addition, the reduction of B16F10 globin-SL8-intron tumor growth was similar after treatment with 18mg/kg of isoginkgetin or IP2, while M2P2 had no effect on tumor growth (Fig. 4C, right panel) . As IP2 treatment reduces tumor growth and is highly soluble in water, we tried to increase the dose injected into mice in order to achieve a greater reduction of tumor growth. However, increasing the dose of IP2 did not improve the antitumor effect on MCA205 Globin-SL8-intron at 24mg/kg but it did enhance it on B16F10 Globin-SL8-intron at 36mg/kg (Fig. 4C , right panel and Supplementary Fig. S7A , right panel). Strikingly, isoginkgetin and M2P2 treatments did not impact the growth of either MCA205 WT or B16F10 WT tumors while IP2 treatment slows down both ( Fig. 4D and Supplementary Fig. S7B ). We observed a 40 to 60% reduction of the growth of MCA205 WT ( Fig. 4D and Supplementary Fig. S6B , left panels) and a 40% reduction of the growth of B16F10 WT ( Fig. 4D and Supplementary Fig. S6B , right panels). Moreover, IP2 treatment was shown to extend the survival of mice with more than 50% survivors 100 days after tumor inoculation (Fig. 4E) Overall, these results suggest a correlation between the increase in PTP-derived antigen presentation observed in vitro and the reduction of the tumor growth in vivo upon treatment.
Interestingly, contrary to isoginkgetin, IP2 treatment slows down the growth of tumors that do not bear the highly immunodominant SL8 epitope derived from PTPs. The difference of efficacy between the two molecules can be due to their biodisponibility, which should be higher for the water-soluble IP2 than for the hydrophobic isoginkgetin, as well as to the use of an increased dose of treatment. We suggest that the splicing inhibitor IP2 potentiates the cell surface apparition of immunodominant epitopes, driving the antitumor response.
IP2 action is dependent on the immune response and creates a long-lasting antitumor response.
To determine the requirement of the immune system and especially of the T-cell response for IP2 efficacy against tumors, we looked at its effect in Nu/Nu athymic nude mice that lack T-cells but and that a change in their presentation at the cell surface in quantity or in quality can lead to a CD8+ T cell-mediated response against cancer.
IP2 treatment alters the MHC I immunopeptidome of tumor cells and modifies the presentation of both conventional and non-conventional MIPs.
To confirm that the enhanced immune response observed after IP2 treatment results from a change in cancer cell immunogenicity, we analyzed the peptide repertoire displayed on the cancer cell surface upon treatment. MCA205 and B16F10 cells were cultured with or without IP2 and peptides eluted from H-2K b and H-2D b molecules were sequenced by mass spectrometry. We first observed that in the presence of IP2 the MHC I immunopeptidome of both MCA205 and B16F10 cells was altered. We identified peptides significantly enriched on the cell surface of MCA205 and B16F10 cells upon treatment and others whose presence was reduced (Fig. 6 ). Interestingly, we found peptides which have been already described in the immune epitope database IEDB but also peptides derived from retained introns ( Table 1 ). This result confirms that retained introns can be a source of peptides for the MHC I presentation pathway and that allegedly non-coding regions of the genome can play a role in tumor cell immunogenicity. Furthermore, table 2 lists the peptides found exclusively after IP2 treatment in the three replicates of the peptide elution experiment. Here again, we found both exonderived and retained intron-derived peptides, most of which have never been described before. We then seek to further characterize the peptides found exclusively after IP2 treatment. In B16F10 cells, there was a significant change in the length of peptides with 8-mers and 9-mers being enriched at the expense of both 11-mers and 12-mers ( Supplementary Fig. S8 ). We then computed the predicted MHC Because IP2 treatment has no impact on the growth of tumors in nude mice ( Figure 5A ) and does not induce apoptosis at the doses tested ( Figure S6C and S6D), it is unlikely that IP2 induces a significant immunogenic cell death. The fact that isoginkgetin or IP2 impact on tumor growth is significantly higher in tumors expressing the PTP-derived SL8 epitope than the WT tumors demonstrates the key role of epitope immunogenicity. In addition, in vitro experiments provide evidence for these splicing inhibitors to induce a quantitatively higher number of presented SL8
peptides, driving the activation of specific T-cells. Conversely, the isoginkgetin derivative M2P2 does not increase the presentation of the SL8-derived PTPs in vitro and, unlike IP2 or isoginkgetin, does not impact the tumor growth in vivo, suggesting that both events may be correlated. Hence, we can reasonably hypothesize that IP2 or isoginkgetin treatments enhance the amount of SL8 peptide at the cancer cell surface in vivo, resulting in the induction of a higher T cell cytotoxic activity against tumor cells followed by tumor growth delay or tumor eradication. Besides, several mechanisms have been described where the presence of highly expressed antigen tumor variants allows the elimination of antigen loss variants, an effect which could explain the action of splicing inhibitors on tumor growth
by an increased load of antigens in tumors (29,32-34).
The PTP model describes the pre-spliced mRNA as the template for the production of PTPs by an alternative translational event occurring in the nucleus. In the study describing this alternative translation, we demonstrated previously that forced nuclear retention of the mRNA encoding the intronic SL8 peptide leads to an increase in the SL8 antigen presentation (18) . Overall, splicing inhibition has been shown to promote pre-RNA accumulation in the nucleus (35,36) . The link between nuclear accumulation of pre-mRNAs and increased antigen presentation is not known so far.
It is tempting to hypothesize that accumulation of pre-mRNA in the nucleus provides more templates for the pioneer round of translation leading to the enrichment of SL8-containing PTPs used as a major source for SL8 direct presentation.
The fact that madrasin, isoginkgetin and IP2, but not M2P2, positively impact PTP-derived antigen presentation shows that a tight regulation of splicing is needed for this effect and encourages future investigations on the link between splicing and antigen presentation. In fact, while M2P2
impacts the splicing of the Globin-SL8-intron gene product in MCA205 cells in a greater extent than isoginkgetin, madrasin and IP2 molecules ( Figure 3E ), it does not increase MCA205 antigen presentation in vitro and does not impact tumor growth in vivo (Figure 4 ), adding more complexity to the correlation between splicing inhibition and antigen presentation. Since most of the splicing inhibitors appear to affect the formation of the basal splicing machinery, one might expect that such modulator affect globally total mRNA splicing. However, it has been reported that there is a specificity of action of each splicing inhibitor depending on certain groups of genes (37,38).
Therefore, these differences of action between IP2 and M2P2 in terms of antigen presentation and inhibition of the spliceosome suggest that M2P2 might act through a different mechanism on a group of genes that is not affected by IP2 treatment. Furthermore, while isoginkgetin, madrasin and IP2
impacts similarly the splicing of the Globin-SL8-intron gene product in B16F10 cells, M2P2 does not impact the splicing in this cell line ( Figure 3D ), which proves that the splicing inhibitory effect is Results are expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 (unpaired student t test).
RNA preparation, RT and qPCR
Cells are transfected with the YFP-Globin-SL8-intron plasmid for 24 hours followed by treatment with drugs for 48 hours. Cells are then harvested and total cellular RNA is extracted and purified using Technologies) . The resulting RNA samples were then used as input for first-strand stranded library preparation using a custom protocol based on dUTP method as described previously (1). Libraries were sequenced on the Illumina HiSeq 4000 sequencer using 50-base pair paired-end read method.
All RNA-seq data were aligned to the mouse genome assembly mm10 with the TopHat2 splicejunction mapper for RNA-Seq reads (version 2.1.1) with default parameters and the Cuffdiff program (version 2.2.1) for all analyses of differential expression. CuffDiff was run using the following parameters: --library-type=fr-firststrand --compatible-hits-norm --library-norm-method geometric --min-reps-for-js-test 2 --dispersion-method per-condition -u -b. In all such analyses, the difference in expression of a gene was considered significant if the q value was less than 0.05 (the Cuffdiff default) and the fold change was superior to 2. Scatter plots were generated using ggplot2 in R environment.
RNA-Seq and generation of the Retained Introns database
Libraries were prepared with TruSeq Stranded Total RNASample preparation kit according supplier recommendations. Briefly the key stages of this protocol are successively, the removal of ribosomal RNA fraction from 1µg of total RNA using the Ribo-Zero Gold Kit, a fragmentation using divalent cations under elevated temperature to obtain approximately 300bp pieces, double strand cDNA synthesis, using reverse transcriptase and random primers, and finally Illumina adapters ligation and cDNA library amplification by PCR for sequencing. Sequencing is then carried out on paired-end 75b
of Illumina HiSeq4000. The Retained Introns database was generated from RNA-seq data (4 replicates for each cell line) according to KMA (KeepMeAround) pipeline which is a suite Python scripts and a R package. Contrary to other existing tools, KMA improves its accuracy by using biological replicates to reduce the number of false positive. The databases were built as follows: (i) Pre-processing step :
Intron coordinates were generated by KMA scripts from the genome reference (GENCODE release GRCm38) and the associated annotation file (GTF file); (ii) Quantification step : RNA-seq files were mapped according to previously defined introns and transcript regions with Bowtie2 v2.3.3.1 and were then quantified with eXpress tool v1.5.2 ; (iii) Post-processing step : Previous generated files were processed by KMA to define a list of retained intron. All expressed introns were considered for the next step. Intron nucleic sequences are then translated in the first three reading frames to create the two databases. Generated amino-acid sequences are then separated according to stop codon and sequences with length lower than 8 amino-acid are discarded. Finally, we identified 135 348 retained introns for MCA205 cells and 140 943 retained introns for B16F10 cells where 124 911 were in common.
HLA ligand elution
MCA205 and B16F10 cells were lysed in buffer containing PBS, 0.25% Sodium Deoxycholate and protease inhibitor (Pierce™ Protease Inhibitor Mini Tablets, EDTA-free, Thermo Fisher) during 1h at 4°C. Lysate was sonicated and centrifugation was performed 1h at 4500rpm at 4°C to pellet debris.
Supernatant was filtered through 0.40 μ m filter and applied on affinity columns overnight. Columns were prepared by coupling Y-3 and B22-249 antibodies to CNBr-activated Sepharose (GE Healthcare)
(1 mg antibody/40 mg Sepharose). On the second day, the columns were eluted in 4 steps using 0.2% TFA. The eluate was filtered through a 3 kDa filter (Pall Nanosep® centrifugal device with Omega membrane) and concentrated using a vacuum centrifuge.
LC-MS/MS acquisition and qualitative analysis
The peptides were desalted using ZipTip C 18 
Quantitative analysis in label-free experiments
Label-free quantification in between subject analysis was performed on raw data with Progenesis-Qi software 4.1 (Nonlinear Dynamics Ltd, Newcastle, U.K.) using the following procedure: (i) chromatograms alignment, (ii) peptide abundances normalization, (iii) statistical analyses of features, and (iv) peptides identification using Sequest server through Proteome Discoverer 2.2 (Thermo Scientific). The mass tolerance was set to 10 ppm for precursor ions and 0.02 Da for fragments. The following modification was used as variable modification: oxidation. No enzyme search was applied.
A decoy search was performed and the significance threshold was fixed to 0.05. MS/MS data were searched against an in house Retained Intron database (MCA205 or B16F10) and Mouse Uniprot extracted database. The resulting files were imported into Progenesis-LC software.
Data availability
The complete proteomics data sets are available in the PRIDE partner repository under the 18 hours. Free soluble SL8 peptide was added to ensure that T-cell activation assays were carried out in non-saturated conditions. Unspecific B3Z T-cell activation was taking into account in the results.
Each graph is one representative of at least four independent experiments.
Data are given as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 (unpaired student t test). indicates that the present study is the first time the peptide has been reported. "IEDB" indicates that the peptide is found in the immune epitope database. "IEDB*" indicates that the peptide is found in the immune epitope database associated with a different source protein. Peptides highlighted in grey are referred as "cancer-related genes" in the Protein Atlas. Peptides with an IC 50 <500nM are referred as strong binders. Data are given as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 (unpaired student t test). c  h  r  1  0  :  3  2  6  4  2  3  6  1  -3  2  8  8  9  6  6  2  L  Q  L  M  L  K  T  I  S  o  d  i  u  m  /  P  o  t  a  s  s  i  u  m  T  r  a  n  s  p  o  r  t  i  n  g  A  T  P  a  s  e  I  n  t  e  r  a  c  t  i  n  g  2   *  N  o  v  e  l   c  h  r  1  1  :  7  0  0  2  7  0  6  7  -7  0  0  2  7 
